Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells

Journal of Orthopaedic Research

Volumn 31, Issue 11, 2013, Pages 1796-1803

  Wang, Yi ^a,b   Hong, Siqi ^a   Li, Ming ^a,b   Zhang, Jiye ^b,c   Bi, Yang ^a,b   He, Yun ^a,b   Liu, Xing ^a,b   Nan, Guoxin ^a,b   Su, Yuxi ^a,b   Zhu, Gaohui ^a,b   Li, Ruidong ^b,c   Zhang, Wenwen ^b,c   Wang, Jinhua ^b,c   Zhang, Hongyu ^b,c   Kong, Yuhan ^b,c   Shui, Wei ^b,c   Wu, Ningning ^b,c   He, Yunfeng ^b,c   Chen, Xian ^b,c   Luu, Hue H ^b   Haydon, Rex C ^b   Shi, Lewis L ^b   He, Tong Chuan ^a,b,c   Qin, Jiaqiang ^a,b,c   more..

^a CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

BMP signaling; BMP9; mesenchymal stem cells; osteogenic differentiation; TGF BMP antagonist

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 9; FOLLISTATIN; NOGGIN; OSTEOGENIC PROTEIN 1; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SMAD8 PROTEIN;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE MINERALIZATION; CELL DIFFERENTIATION; EMBRYO; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; UPREGULATION;

BMP SIGNALING; BMP9; MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; TGFΒ/BMP ANTAGONIST;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEINS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; GROWTH DIFFERENTIATION FACTORS; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; SIGNAL TRANSDUCTION; SMAD PROTEINS;

EID: 84884903343     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22427     Document Type: Article

References (50)

1. Attisano L, Wrana JL,. 2002. Signal transduction by the TGF-beta superfamily. Science 296: 1646-1647.
2. Deng ZL, Sharff KA, Tang N, et al. 2008. Regulation of osteogenic differentiation during skeletal development. Front Biosci 13: 2001-2021.
3. Luu HH, Song WX, Luo X, et al. 2007. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 25: 665-677.
4. Prockop DJ,. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
5. Rastegar F, Shenaq D, Huang J, et al. 2010. Mesenchymal stem cells: molecular characteristics and clinical applications. World J Stem Cells 2: 67-80.
6. Shenaq DS, Rastegar F, Petkovic D, et al. 2010. Mesenchymal progenitor cells and their orthopedic applications: forging a path towards clinical trials. Stem Cells Int 2010: 519028.
7. Hermann A, Gastl R, Liebau S, et al. 2004. Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci 117: 4411-4422.
8. Keilhoff G, Goihl A, Langnase K, et al. 2006. Transdifferentiation of mesenchymal stem cells into Schwann cell-like myelinating cells. Eur J Cell Biol 85: 11-24.
9. Wislet-Gendebien S, Wautier F, Leprince P, et al. 2005. Astrocytic and neuronal fate of mesenchymal stem cells expressing nestin. Brain Res Bull 68: 95-102.
10. Makino S, Fukuda K, Miyoshi S, et al. 1999. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103: 697-705.
11. Hogan BL,. 1996. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 10: 1580-1594.
12. Zhao GQ,. 2003. Consequences of knocking out BMP signaling in the mouse. Genesis 35: 43-56.
13. Cheng H, Jiang W, Phillips FM, et al. 2003. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A: 1544-1552.
14. Kang Q, Sun MH, Cheng H, et al. 2004. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 11: 1312-1320.
15. Luther G, Wagner ER, Zhu G, et al. 2011. BMP-9 Induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potentia. Curr Gene Ther 11: 229-240.
16. Peng Y, Kang Q, Cheng H, et al. 2003. Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem 90: 1149-1165.
17. Peng Y, Kang Q, Luo Q, et al. 2004. Inhibitor of DNA binding/ differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 32941-32949.
18. Luo Q, Kang Q, Si W, et al. 2004. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279: 55958-55968.
19. Sharff KA, Song WX, Luo X, et al. 2009. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 284: 649-659.
20. Huang E, Zhu G, Jiang W, et al. 2012. Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells. J Bone Miner Res 27: 1566-1575.
21. Luo J, Tang M, Huang J, et al. 2010. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem 285: 29588-29598.
22. Song JJ, Celeste AJ, Kong FM, et al. 1995. Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 136: 4293-4297.
23. Lopez-Coviella I, Berse B, Krauss R, et al. 2000. Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 289: 313-316.
24. Walsh DW, Godson C, Brazil DP, et al. 2010. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20: 244-256.
25. Zakin L, De Robertis EM,. 2010. Extracellular regulation of BMP signaling. Curr Biol 20: R89-R92.
26. Daluiski A, Engstrand T, Bahamonde ME, et al. 2001. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27: 84-88.
27. Luo X, Chen J, Song WX, et al. 2008. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88: 1264-1277.
28. Haydon RC, Zhou L, Feng T, et al. 2002. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8: 1288-1294.
29. Tang N, Song WX, Luo J, et al. 2009. BMP9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signaling. J Cell Mol Med 13: 2448-2464.
30. He BC, Chen L, Zuo GW, et al. 2010. Synergistic antitumor effect of the activated PPAR gamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245.
31. He BC, Gao JL, Zhang BQ, et al. 2011. Tetrandrine inhibits Wnt/beta-catenin signaling and suppresses tumor growth of human colorectal cancer. Mol Pharmacol 79: 211-219.
32. Zhang W, Deng ZL, Chen L, et al. 2010. Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PloS ONE 5: e11917.
33. He TC, Chan TA, Vogelstein B, et al. 1999. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
34. He TC, Sparks AB, Rago C, et al. 1998. Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
35. He TC, Zhou S, da Costa LT, et al. 1998. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514.
36. Luo J, Deng ZL, Luo X, et al. 2007. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2: 1236-1247.
37. Kang Q, Song WX, Luo Q, et al. 2009. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 18: 545-559.
38. Si W, Kang Q, Luu HH, et al. 2006. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26: 2955-2964.
39. Bi Y, Huang J, He Y, et al. 2009. Wnt antagonist SFRP3 inhibits the differentiation of mouse hepatic progenitor cells. J Cell Biochem 108: 295-303.
40. Zhu GH, Huang J, Bi Y, et al. 2009. Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells. Differentiation 78: 195-204.
41. Huang J, Bi Y, Zhu GH, et al. 2009. Retinoic acid signalling induces the differentiation of mouse fetal liver-derived hepatic progenitor cells. Liver Int 29: 1569-1581.
42. Chen L, Jiang W, Huang J, et al. 2010. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res 25: 2447-2459.
43. Huang E, Bi Y, Jiang W, et al. 2012. Conditionally immortalized mouse embryonic fibroblasts retain proliferative activity without compromising multipotent differentiation potential. PloS ONE 7: e32428.
44. Zhou L, An N, Jiang W, et al. 2002. Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. Biotechniques 33: 1126-1128, 1130, 1132 passim.
45. Smith WC, Harland RM,. 1992. Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell 70: 829-840.
46. Groppe J, Greenwald J, Wiater E, et al. 2002. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642.
47. McMahon JA, Takada S, Zimmerman LB, et al. 1998. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev 12: 1438-1452.
48. Brunet LJ, McMahon JA, McMahon AP, et al. 1998. Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280: 1455-1457.
49. Devlin RD, Du Z, Pereira RC, et al. 2003. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144: 1972-1978.
50. Wu XB, Li Y, Schneider A, et al. 2003. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 112: 924-934.